| Next 10 |
Ad
VERV News and Press Verve Therapeutics Inc.
News | Verve Therapeutics Inc. (NASDAQ:VERV)
-
2025-04-22 21:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
2025-04-19 07:40:44 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . Read the full article on Seeking Alpha For further details see: What Moved Markets This Week
-
2025-04-18 18:36:46 ET Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics ' (NASDAQ: VERV) big stock price leap this week. By the time the dust cleared, the biotech company's shares soared 40% higher over the period, accor...
-
2025-04-17 16:11:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results Wall Street Lunch: Obesity Pill Progress Eli Lilly: Still Great, But Still Too Expensive Even As Earnings Near Why...
-
2025-04-17 12:29:34 ET Here are the latest rating upgrades from Seeking Alpha analysts: Advanced Micro Devices ( NASDAQ: AMD ). Hold to buy by Kenio Fontes . "The Company's forward P/E of ~19x for 2025 EPS offers a margin of safety, prompting an upgrade in the stock rating...
-
2025-04-16 10:56:15 ET Summary VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102’s development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV&...
-
2025-04-15 12:43:00 ET Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session. Yesterday, Verve published promising data from its Hear...
-
2025-04-15 10:38:30 ET More on Verve Therapeutics Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2 Verve jumps after early-stage trial data ...
-
2025-04-14 08:29:18 ET More on Verve Therapeutics Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2 Verve Therapeutics wins FDA fast track st...
-
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically s...
Stock Information
Get VERV Alerts
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
1.04% G/L:
$5.76 Last:
1,655,571 Volume:
$5.72 Open:
$5.76 Close:
Verve Therapeutics Inc. Website:
Ad
-
2025-04-22 21:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
2025-04-18 18:36:46 ET Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics ' (NASDAQ: VERV) big stock price leap this week. By the time the dust cleared, the biotech company's shares soared 40% higher over the period, accor...
-
2025-04-15 12:43:00 ET Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session. Yesterday, Verve published promising data from its Hear...